Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Robin J Shattock

Showing results (201-210 of 211) with videos related to

Pageof 22
Sort By:
Frontiers in Immunology|May 21, 2019
Envelope-Specific Recognition Patterns of HIV Vaccine-Induced IgG Antibodies Are Linked to Immunogen Structure and SequenceYuka Nadai, Kathrin Held, Sarah Joseph, et al.
Antimicrobial Agents and Chemotherapy|January 27, 2006
In vitro preclinical testing of nonoxynol-9 as potential anti-human immunodeficiency virus microbicide: a retrospective analysis of results from five laboratoriesBrigitte E Beer, Gustavo F Doncel, Fred C Krebs, et al.
The Lancet. Infectious Diseases|April 14, 2024
An investigation of trachoma vaccine regimens by the chlamydia vaccine CTH522 administered with cationic liposomes in healthy adults (CHLM-02): a phase 1, double-blind trialKatrina M Pollock, Álvaro H Borges, Hannah M Cheeseman, et al.
Advanced Materials (Deerfield Beach, Fla.)|February 15, 2026
Modular Supramolecular Polycations Enable Efficient Delivery of Diverse RNA Therapeutics and VaccinesRafał Jerzy Kopiasz, Hadijatou J Sallah, Robert J Cavanagh, et al.
Eclinicalmedicine|January 23, 2023
COVAC1 phase 2a expanded safety and immunogenicity study of a self-amplifying RNA vaccine against SARS-CoV-2Alex J Szubert, Katrina M Pollock, Hannah M Cheeseman, et al.
Frontiers in Immunology|February 6, 2023
Systematic comparison of HIV-1 Envelope-specific IgG responses induced by different vaccination regimens: Can we steer IgG recognition towards regions of viral vulnerability?Augusta Horvath, Lisa Rogers, Georgios Pollakis, et al.
Eclinicalmedicine|January 19, 2022
Safety and immunogenicity of a self-amplifying RNA vaccine against COVID-19: COVAC1, a phase I, dose-ranging trialKatrina M Pollock, Hannah M Cheeseman, Alexander J Szubert, et al.
European Journal of Immunology|August 6, 2021
A pair of noncompeting neutralizing human monoclonal antibodies protecting from disease in a SARS-CoV-2 infection modelAntonia Sophia Peter, Edith Roth, Sebastian R Schulz, et al.
Nature Communications|May 31, 2019
Structure and immunogenicity of a stabilized HIV-1 envelope trimer based on a group-M consensus sequenceKwinten Sliepen, Byung Woo Han, Ilja Bontjer, et al.
Plos Pathogens|August 4, 2015
Human Non-neutralizing HIV-1 Envelope Monoclonal Antibodies Limit the Number of Founder Viruses during SHIV Mucosal Infection in Rhesus MacaquesSampa Santra, Georgia D Tomaras, Ranjit Warrier, et al.
Pageof 22

Showing results (201-210 of 211) with videos related to

Sort By:
Pageof 22
Frontiers in Immunology|May 21, 2019
Envelope-Specific Recognition Patterns of HIV Vaccine-Induced IgG Antibodies Are Linked to Immunogen Structure and SequenceYuka Nadai, Kathrin Held, Sarah Joseph, et al.
Antimicrobial Agents and Chemotherapy|January 27, 2006
In vitro preclinical testing of nonoxynol-9 as potential anti-human immunodeficiency virus microbicide: a retrospective analysis of results from five laboratoriesBrigitte E Beer, Gustavo F Doncel, Fred C Krebs, et al.
The Lancet. Infectious Diseases|April 14, 2024
An investigation of trachoma vaccine regimens by the chlamydia vaccine CTH522 administered with cationic liposomes in healthy adults (CHLM-02): a phase 1, double-blind trialKatrina M Pollock, Álvaro H Borges, Hannah M Cheeseman, et al.
Advanced Materials (Deerfield Beach, Fla.)|February 15, 2026
Modular Supramolecular Polycations Enable Efficient Delivery of Diverse RNA Therapeutics and VaccinesRafał Jerzy Kopiasz, Hadijatou J Sallah, Robert J Cavanagh, et al.
Eclinicalmedicine|January 23, 2023
COVAC1 phase 2a expanded safety and immunogenicity study of a self-amplifying RNA vaccine against SARS-CoV-2Alex J Szubert, Katrina M Pollock, Hannah M Cheeseman, et al.
Frontiers in Immunology|February 6, 2023
Systematic comparison of HIV-1 Envelope-specific IgG responses induced by different vaccination regimens: Can we steer IgG recognition towards regions of viral vulnerability?Augusta Horvath, Lisa Rogers, Georgios Pollakis, et al.
Eclinicalmedicine|January 19, 2022
Safety and immunogenicity of a self-amplifying RNA vaccine against COVID-19: COVAC1, a phase I, dose-ranging trialKatrina M Pollock, Hannah M Cheeseman, Alexander J Szubert, et al.
European Journal of Immunology|August 6, 2021
A pair of noncompeting neutralizing human monoclonal antibodies protecting from disease in a SARS-CoV-2 infection modelAntonia Sophia Peter, Edith Roth, Sebastian R Schulz, et al.
Nature Communications|May 31, 2019
Structure and immunogenicity of a stabilized HIV-1 envelope trimer based on a group-M consensus sequenceKwinten Sliepen, Byung Woo Han, Ilja Bontjer, et al.
Plos Pathogens|August 4, 2015
Human Non-neutralizing HIV-1 Envelope Monoclonal Antibodies Limit the Number of Founder Viruses during SHIV Mucosal Infection in Rhesus MacaquesSampa Santra, Georgia D Tomaras, Ranjit Warrier, et al.
Pageof 22